Tipsheet
What matters at India’s listed companies
Earnings · Agriculture · Micro cap

Genomic Valley Biotech revenue collapsed 68% to ₹26.75 lakhs in FY26

The biotech firm's top line shrank from ₹84.84 lakhs to ₹26.75 lakhs in one year. Net profit followed, falling to ₹3.03 lakhs.


Mkt cap₹10.19 cr
P/E339.71×
ROE9.13%
Debt / eq.0.00
68% Decline in annual revenue from FY25 to FY26.

What's new

  • Annual revenue fell 68% to ₹26.75 lakhs from ₹84.84 lakhs the prior year.
  • Net profit dropped to ₹3.03 lakhs from ₹35.6 lakhs in FY25.
  • Board appointed Navjyoti Kumar Jha as internal auditor for FY27.

Why this matters

Genomic Valley Biotech has lost over two-thirds of its revenue in a single year, with profit down 91%. The company is still in the black, but the operational scale is now so small that its viability as a going concern is the immediate question.

What we're watching

  • Management's explanation for the near-total revenue erosion.
  • Whether the new auditor flags going-concern or compliance issues.
  • Next quarter's results to see if the business has a floor.

The full read

Genomic Valley Biotech had a terrible year. Revenue fell 68% to ₹26.75 lakhs from ₹84.84 lakhs. Net profit dropped to ₹3.03 lakhs from ₹35.6 lakhs. The business is still nominally profitable, but the scale is now trivial. The board also appointed a new internal auditor, a standard annual move. There is no explanation given for the collapse. The open question is what remains of the operational base that generated ₹84.84 lakhs just a year ago. One year.

Questions answered

How severe was Genomic Valley Biotech's financial decline in FY26?
Revenue fell 68% to ₹26.75 lakhs from ₹84.84 lakhs. Net profit dropped 91% to ₹3.03 lakhs. Both top and bottom lines were decimated in a single year.
Why was a new internal auditor appointed?
Navjyoti Kumar Jha was named internal auditor for FY27. The filing states the appointment was for oversight of compliance and internal controls, a standard annual requirement.
Is the company still profitable?
Yes, but barely. Genomic Valley Biotech reported a net profit of ₹3.03 lakhs, down from ₹35.6 lakhs. The profit margin has been crushed along with revenue.
What does this mean for the company's operational base?
The business shrank from ₹84.84 lakhs to ₹26.75 lakhs in revenue. The filing offers no explanation, leaving the question of what operational model remains unanswered.
Mentioned: Genomic Valley Biotech · ₹26.75 lakhs revenue · ₹3.03 lakhs net profit
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Genomic Valley Biotech Ltd.

Agriculture
₹9 cr
P/E 292.72×

Latest quarter · Mar 2026

Sales₹0 cr
Net profit−₹0 cr
Op. margin+10.5%
EPS−₹0.02

Strength & growth

Debt / equity0.00×
Current ratio5.73×
Sales CAGR+9.3%
Financials via Tijori — a research aid, not investment advice.GVBL on Tijori